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Abstract
Background: The rapid production and incorporation of engineered nanomaterials into consumer products
alongside research suggesting nanomaterials can cause cell death and DNA damage (genotoxicity) makes in vitro
assays desirable for nanosafety screening. However, conflicting outcomes are often observed when in vitro and in
vivo study results are compared, suggesting more physiologically representative in vitro models are required to
minimise reliance on animal testing.
Method: BASF Levasil® silica nanoparticles (16 and 85 nm) were used to adapt the 3D reconstructed skin
micronucleus (RSMN) assay for nanomaterials administered topically or into the growth medium. 3D dose-
responses were compared to a 2D micronucleus assay using monocultured human B cells (TK6) after standardising
dose between 2D / 3D assays by total nanoparticle mass to cell number. Cryogenic vitrification, scanning electron
microscopy and dynamic light scattering techniques were applied to characterise in-medium and air-liquid interface
exposures. Advanced transmission electron microscopy imaging modes (high angle annular dark field) and X-ray
spectrometry were used to define nanoparticle penetration / cellular uptake in the intact 3D models and 2D
monocultured cells.
Results: For all 2D exposures, significant (p < 0.002) increases in genotoxicity were observed (≥100 μg/mL)
alongside cell viability decreases (p < 0.015) at doses ≥200 μg/mL (16 nm-SiO2) and ≥100 μg/mL (85 nm-SiO2). In
contrast, 2D-equivalent exposures to the 3D models (≤300 μg/mL) caused no significant DNA damage or impact
on cell viability. Further increasing dose to the 3D models led to probable air-liquid interface suffocation.
Nanoparticle penetration / cell uptake analysis revealed no exposure to the live cells of the 3D model occurred due
to the protective nature of the skin model’s 3D cellular microarchitecture (topical exposures) and confounding
barrier effects of the collagen cell attachment layer (in-medium exposures). 2D monocultured cells meanwhile
showed extensive internalisation of both silica particles causing (geno)toxicity.
Conclusions: The results establish the importance of tissue microarchitecture in defining nanomaterial exposure,
and suggest 3D in vitro models could play a role in bridging the gap between in vitro and in vivo outcomes in
nanotoxicology. Robust exposure characterisation and uptake assessment methods (as demonstrated) are essential
to interpret nano(geno)toxicity studies successfully.
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Abbreviations: 16 nm-SiO2, BASF Levasil® 200 silicon dioxide nanoparticles; 2DM, 89 % RPMI 1640, 10 % horse serum,
1 % glutamine used to culture TK6 cells in 2D assays; 3DM, MatTek Corporation’s New Maintenance growth medium
used to culture the 3D EpiDerm™ tissues; 85 nm-SiO2, BASF Levasil® 50 silicon dioxide nanoparticles; ALI, Air-liquid
interface; chemical-RSMN, Reconstructed skin micronucleus assay protocol developed previously [30] for chemical test
articles; cryo-SEM, Cryogenic vitrification and scanning electron microscopy; cyt B, Cytochalasin B; DLS, Dynamic light
scattering; EDX, Energy dispersive X-ray spectrometry; HAADF-STEM, High angle annular dark-field scanning
transmission electron microscopy; MN, Micronucleus; nano-RSMN, Reconstructed skin micronucleus assay protocol
developed here for nano test articles; RPD, Relative population doubling; RSMN, Reconstructed skin micronucleus;
TEM, Transmission electron microscopy
Background
The nano-scaling of materials has led to the identification
of enhanced mechanical, optical, electrical, catalytic and
magnetic properties relative to that of micro-scaled
formulations [1–3]. Consequently, nanomaterials increas-
ingly find applications in commercial products as adoption
of nanotechnology undergoes rapid global expansion [4].
Human exposure to engineered nanomaterials is therefore
already occurring and looks set to rise in the future.
Though it is size that permits desirable functionality, it
is also known to facilitate nanomaterial uptake, tissue
penetration and systemic distribution in the body [5, 6].
Concern arises as research shows nanomaterials can
stimulate inflammatory responses, initiate oxidative
stress and cause DNA damage (genotoxicity) and cell
death (cytotoxicity) [5, 7–9]. This has necessitated the
development of robust test protocols for nanomaterial
safety assessment, with a variety of in vitro and in vivo
test methodologies examined to date. It has become
clear however that assays designed for chemical hazard
assessment may be unsuitable or require considerable
optimisation for nanoscale test articles [3, 9–11].
Since pathophysiologic effects in vivo are influenced
by both toxicokinetics (i.e., distribution, accumulation
and clearance), as well as toxicodynamics (i.e., tissue-
and/or cell-specific responses); the use of in vitro tools
primarily remains restricted to hazard identification [12].
Furthermore, conflicting results are often found when
the results of similar in vitro studies or in vitro and in
vivo outcomes are compared. This has raised concern
regarding the appropriateness of current in vitro as-
says for nanoscale test articles, and has encouraged
continued reliance on in vivo safety testing strategies
for nanomaterials [10, 13]. However, to keep pace
with the rapid growth of the nanotechnology sector,
and societal and economic pressures to replace, re-
duce or refine the need for animals in consumer
product safety assessments, there is a growing need
for robust in vitro alternatives [1].
The conflicting outcomes noted between in vitro and
in vivo nanosafety studies have been partially attributed
to insufficient particle characterisation in the biological
matrix of the employed test system, where bio-nano
interactions (e.g., serum protein-to-particle binding) and
agglomeration processes are known to modulate nano-
material surface chemistries and the kinetics of dosim-
etry [14, 15]. Ultimately these processes affect what is
presented at the cell surface and the probability that
cellular uptake will occur [13, 16]. Consequently, charac-
terising exposure in the biological environment and
quantifying cellular uptake have been highlighted as crit-
ical factors for successful interpretation and comparison
of nanotoxicological assessments in vitro [17, 18].
There is also wider concern, for both chemical com-
pounds and nanomaterial safety assessment perspectives,
that assays based on two-dimensional monocultured
cells do not represent the three dimensional complexity
of in vivo systems. This is thought to constitute a major
factor in the over-predictivity associated with in vitro as-
says (i.e., low specificity), as three-dimensional (3D) cellu-
lar microarchitectures in vivo may constitute a barrier to
distribution and absorption that is not represented in 2D
monocultures [10, 19–23]. It has therefore been suggested
that the development of in vitro assays with 3D cellular
structures is critical for ‘bridging the gaps’ between in
vitro and in vivo outcomes [10].
Despite existing in a variety of different formats, 3D in
vitro models share the characteristic that their constitu-
ent cells combinatorially establish a 3D microarchitec-
ture. It has been shown that that this 3D structure can
influence diverse cellular functionalities including prolif-
eration, differentiation, migration, invasion and cell
death [10]. To date, the majority of 3D culture systems
applied in nanotoxicology have been ‘spheroid’ models
in which a tight ball of cells is established and employed.
Quantum dot, gold, iron oxide, carbon nanotube and
silica nanoparticle exposures to such spheroidal cultures
established from macrophage and liver cells have all
shown different outcomes in comparison to 2D mono-
cultures: more specifically, toxicity and tissue penetra-
tion have been reported to be reduced, and restricted to
the outermost layers of the spheroids [10, 24–27]. It is
to be noted however that these studies primarily focused
on the potential for nanomaterials to induce cytotoxicity,
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whilst arguably the potential for carcinogenesis and
heritable genetic alterations via DNA damage and muta-
genesis could be considered the more concerning out-
comes associated with nanomaterial exposures [7].
The 2D in vitro micronucleus (MN) assay is the gold
standard test system for the detection of chromosomal
damage induced by an exogenous agent, and nano-
specific guidance for conducting test article assessments is
becoming defined [11, 28, 29]. Despite the establishment
of this guidance however, the short-comings of any 2D
system for nano assessment are well acknowledged and
there is general agreement that the utility of recently-
developed 3D alternatives needs to be explored and evalu-
ated [10]. Recently, intensive international efforts have
gone into the development of a 3D reconstructed skin
micronucleus (RSMN) assay for chemical test articles
(chemical-RSMN [30]), which uses the commercially
available EpiDermTM human epidermis model (MatTek
Corporation). The development and pre-validation of this
3D assay has been well documented [22, 30–36].
Given that the 7th Amendment to the Cosmetics Direct-
ive in Europe now prohibits the testing of cosmetics and
cosmetic ingredients in vivo, alternative approaches to
assess dermal exposures are critical. Thus, developing the
3D RSMN assay for nanosafety assessment is of significant
interest as the health and fitness industry is increasingly
using nanomaterials in personal care products, cosmetics
and clothing [37]. Furthermore, the EpiDerm™ model has
already shown promise for nanosafety applications includ-
ing the assessment of nanoparticle skin irritation [38, 39]
and percutaneous absorption [40].
This investigation used silica nanoparticles, dermal
exposure to which is a concern due to their incorpor-
ation in adhesives, polishes and varnishes, photocopier
toner, as well as their use as food stabilizing agents and
as cosmetic additives [37, 41], to determine the utility of
the RSMN protocol for nanosafety assessment. The
establishment of equivalent 2D/3D nanoparticle doses
permitted dose-response comparisons between the de-
veloped, 3D ‘nano-RSMN’ method and a ‘traditional’ 2D
micronucleus assay, carried out using monocultured
human B lymphoblastoid cells (TK6). TK6 cells were
chosen for the 2D studies because their use is recom-
mended in the existing Organisation for Economic Co-
operation and Development (OECD) micronucleus assay
test guideline (i.e., Test Guideline 487); thus, their use for
the in vitro MN assay has been extensively validated and
internationally-accepted [42]. Comparing the outcomes of
a ‘typical’ 2D in vitro micronucleus test conducted accord-
ing to the OECD test guideline with a ‘new’ version of the
assay employing 3D in vitro models was therefore deemed
the appropriate starting point for a comparison between
2D and 3D forms of the assay versions. Alongside, cryo-
genic vitrification, scanning electron microscopy and
dynamic light scattering techniques are demonstrated to
characterise 2D in-medium and 3D air-liquid interface
exposures. Finally, advanced transmission electron im-
aging modes were used to define nanoparticle penetration
in the intact, 3D architecture of the EpiDerm™ tissues and
cellular uptake in the 2D monocultures facilitating robust
2D/3D dose-response comparison.
Results
Primary nanoparticle physico-chemical characterisation
This study used BASF Levasil® 200 and Levasil® 50
amorphous silica nanoparticles to optimise a 3D RSMN
assay for nanomaterial test articles. Transmission elec-
tron microscopy (TEM) indicated both particles were
spherical and had a relatively smooth surface morph-
ology (Fig. 1a and b). Primary size (i.e., single particle)
measurements from electron micrographs determined
the average diameter of the Levasil® 200 to be 16.4 nm
(manufacturer specified 15 nm) and Levasil® 50 to be
85.1 nm (manufacturer specified 55 nm) (Table 1). There-
fore, text references hereafter refer to 16 nm-SiO2 or
85 nm-SiO2, respectively. No evidence of regular lattice
planes was found at higher magnification confirming the
expected amorphous structure. Nanoparticle composition
and the presence of trace contaminants was investigated
using energy dispersive X-ray (EDX) spectrometry. Com-
paring a blank area of the TEM grid to an area containing
nanoparticles revealed a large shift in the ratio of the oxy-
gen and silicon peaks, confirming the silicon dioxide
particle composition (Fig. 1c). No evidence of unexpected
elemental traces (e.g., impurities or unexpected suspen-
sion phase contaminants) was found by EDX. Dynamic
Light Scattering (DLS) analysis at 300 μg/mL in ultra-pure
water (MilliQ, 18MΩ·cm) showed number distribution
peak maxima at 17 nm and 92 nm, respectively, for
the 16 nm-SiO2 and 85 nm-SiO2. DLS size ranges in
water were therefore concurrent to the primary sizes
established by TEM, suggesting manufacturer-supplied
suspensions were colloidally stable. Surface charge
(zeta potential) measurements were strongly negative
(< −40 mV) for both particles further indicative of col-
loidal stability in water and consistent with silicon
dioxide’s surface chemistry of negative, unbound oxy-
gen groups (Table 1 and Fig. 1d). Further TEM im-
ages, particle size distributions and EDX spectra are
available in Additional files 1, 2 and 3.
Development and optimisation of a reconstructed skin
micronucleus (RSMN) assay protocol for nanomaterials
(nano-RSMN)
Two exposure routes for the 3D skin models were con-
sidered in this study: nanoparticles were either applied
topically onto the surface of the stratum corneum, mim-
icking dermal deposition, or were administered directly
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into the growth medium (in-medium), simulating circu-
latory exposure (Fig. 2a and b). Maintenance of an air-
liquid interface (ALI) at the dermal surface of the model
is known to be essential to model viability. The previ-
ously published chemical-RSMN method [30] therefore
recommends the use of 10 μL acetone, which is com-
monly used for in vivo dermal exposures, as a delivery
vehicle because it quickly evaporates, leaving a dry sur-
face to maintain the ALI. For this reason, and because it
was possible to prepare stable colloidal suspensions, the
silica nanoparticles used here were also administered in
this way. The acetone evaporated in 15–20 s, depositing
the particles directly onto the tissue surface.
One of the most important considerations in the MN
assay is ensuring that cells complete mitosis during the
exposure period, as this is required for lagging chromo-
somes or chromosomal fragments (i.e. resulting from
exposure) to manifest as scorable MN events. Identifica-
tion of cells that have undergone division is most com-
monly achieved using cytochalasin B (cyt B) to block
cytokinesis, leading to the formation of readily identifi-
able binucleated cells [42]. However, cyt B acts through
actin inhibition and it can inhibit endocytosis processes
known to be essential for the active cellular uptake of
many nanomaterials. It is therefore important to modify
chemical MN assay methodologies to permit a period of
nanomaterial exposure in absence of cyt B prior to its
sequential addition [11, 28, 29, 42]. For this reason, and
in order to present a test methodology that was as com-
parable as possible to the 24 h exposure-then-recovery
regime (i.e., a sequential cyt B regime) employed for the 2D
MN assay, the ‘nano-RSMN’ method shown in Fig. 2c was
developed to permit enumeration of induced, cytokinesis-
blocked MNs in the 3D system. The protocol uses a single,
24 h test article exposure (– cyt B) followed by 42 h recov-
ery phase (+ cyt B) to allow the primary cells of the 3D
model time to divide.
To study the impact of cyt B and acetone on tissue
growth and differentiation, unexposed control tissues
were harvested on each day of the assay, stained with
haemotoxylin and eosin and optically imaged in cross-
section (Fig. 3a–d). From arrival to harvest, the stratum
corneum layer was seen to increase in thickness (from
~22 μm to 58 μm) as dividing basal cells moved upwards
and differentiated to form new stratum corneum. The
multi-layered structure of the model was revealed with
distinct basal cell, stratum spinosum, granulosum and
corneum layers identifiable (Fig. 3a). Negative control
Fig. 1 BASF Levasil® silicon dioxide nanoparticle primary characterisation: Bright field TEM micrographs of (a) 16 nm-SiO2, and (b) 85 nm-SiO2,
allowed primary particle size, shape and morphology to be assessed. c Typical particle EDX spectrum relative to background confirming the
presence of silicon and oxygen with no detectable contaminants (copper and carbon due to TEM grid and support film). d Schematic illustrating
the negative surface charge of SiO2 particles, due to unbound surface oxygen groups
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Table 1 Levasil® nanoparticle primary characterisation: TEM in conjunction with EDX spectroscopy was used to determine primary size distributions, shape / morphology,
crystallinity, composition and purity. DLS determined particle colloidal stability/agglomeration (hydrodynamic diameter) and also particle surface charge (zeta potential) in
as-manufactured aqueous solution
Product Name Text Reference Manufacturer
Specified Size
(diameter, nm)
Transmission Electron Microscopy/Energy Dispersive X-ray
Spectroscopy
Material
Density
(g/cm3)
Material
Refractive
Index
Dynamic Light Scattering (peak analysis of distributions by
particle number)
Primary Size: average
diameter, nm ± standard
deviation (range)
Shape/
Morphology
Crystallinity/
Composition/
Purity Contaminant
free?
Agglomeration:
(hydrodynamic diameter, nm)
Surface Charge (mV) Surface chemistry
aqueous dispersion; 300 μg/mL
Modal size
(distribution
peak max)
Size
Range (99 %
distribution)
Polydispersity
ndex (range)
Zeta Potential ±
SD (Solution pH)
Levasil® 200
(aqueous solution)
16 nm-SiO2 15 16.4 ± 5.3 (8 – 42) spherical/
smooth
Amorphous
SiO2, yes
2.65 1.54 17 9 - 32 0.02 - 0.08 -55.3 ± 2.3 (pH 7.8) negative due to
unbound surface
oxygen
Levasil® 50
(aqueous solution)
85 nm-SiO2 55 85.1 ± 23.7 (41 – 159) spherical/
smooth
Amorphous
SiO2, yes
2.65 1.54 92 50 - 164 0.21 - 0.22 -63.2 ± 3.8 (pH 9.4)
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tissues at the harvest time-point were then compared to
tissues dosed with 10 μL topical or in-medium acetone
and cultured using cyt B according to the defined nano-
RSMN protocol (Fig. 2c). Encouragingly, no difference in
tissue structure or morphology caused by solvent or cyt B
inclusion was identified. Harvest time-point stratum cor-
neum and basal cell thicknesses remained highly similar
to untreated control (Fig. 3d–f ).
Despite differences in study duration, number of
acetone (dosing) exposures and use of a sequential/
shorter exposure cyt B regime, the developed nano-
RSMN method also encouragingly yielded comparable
binucleated cell frequencies (p > 0.17, n = 3) to those
obtained using the original chemical-RSMN [30] approach.
The binucleate frequency data from these optimisation
experiments are presented in Additional file 4.
Dosing and characterising nanomaterial exposures in the
2D and 3D assays
As topical silica nanoparticle exposures were evaporation-
deposited onto the tissue surface, the mass/volume (e.g.,
μg/mL) 2D dosing approach could not be applied directly
when dosing the 3D models. Dose between 2D and 3D
assays was therefore normalised in terms of total nanopar-
ticle mass to the total number of cells in each assay (see
Methods). In this way, ‘3D equivalent’ total mass doses of
150 μg, 300 μg and 450 μg were established to allow
comparison to the 100 μg/mL, 200 μg /mL and 300 μg
/mL exposures used in the 2D cytotoxicity (relative
population doubling (RPD)) and MN assays. Alternative
dose metrics including the 3D equivalent total mass
doses per unit area (topical exposures) and per unit
volume (in-medium exposures) are provided in Table 2.
To characterise 3D topical exposures, particle depos-
ition state was preserved immediately after dosing by
vitrification in liquid nitrogen [43], and was subse-
quently imaged using cryogenic scanning electron mi-
croscopy (cryo-SEM) (Fig. 4). For both the 16 nm-SiO2
and 85 nm-SiO2, the lower total mass doses (≤300 μg)
resulted in patchy, heterogenous surface coverage, with
some areas of the tissue surface found to remain completely
free of nanoparticles. With increasing dose (≥450 μg) how-
ever, coverage became increasingly layered and thick
enough to mask the surface features of the underlying
tissue. Areas of unexposed stratum corneum became less
common and were found only at the far peripheries of the
tissue surface for the highest (1000 μg) exposures. Further
cryo-SEM images are presented in Additional files 5 and 6.
The use of different growth media with the 2D and 3D
models was unavoidable due to their different physio-
logical requirements, and the need for specific growth
factors to maintain the structure, growth and differenti-
ation of the 3D model. In order to characterise the
surface charge (zeta potential) and agglomeration state
Fig. 2 The reconstructed skin micronucleus assay optimised for nanomaterial test articles: (a) Six-well plate containing MatTek Corporation’s 3D
epidermis (EpiDermTM) tissue models in trans-well inserts. b Schematic diagram of a single well (cross-section) highlighting the two nanoparticle
exposure routes utilised with the 3D models in this study: nanoparticles were either inoculated onto the topical surface or administered into the
growth medium. c The developed day-by-day ‘nano-RSMN’ assay protocol from receipt of tissues to harvest detailing dosing, media changes and
sequential cyt B regime
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Fig. 3 3D model structure, growth and differentiation across the nano-RSMN protocol: The EpiDermTM model is a structurally differentiated, multi-layered
model (a) of the human epidermis created from primary human keratinocytes. From arrival (a) to harvest (d) untreated control tissues in absence of cyt B
were grown and imaged daily. The stratum corneum barrier layer increased in thickness as dividing keratinocytes moved upwards and differentiated. (Note:
the trans-well insert layer detached during image preparation, (a, d). Comparison of the untreated control tissue (d) to tissues exposed to cyt B and acetone
via the topical (e) and medium (f) exposure routes at the harvest time-point showed no differences in tissue development/structure
Table 2 2D/3D dose normalisation and alternative metrics: Dose between 2D and 3D in vitro test systems was standardised in
terms of total nanoparticle mass to total cell number at time of dosing (Table Left) (see Methods). For each exposure route used
here, alternative dose-metrics (as applicable) are also presented (Table Right) to facilitate comparison. In-medium exposures (2D/3D
In-Medium) are provided in total mass (μg), mass/volume (μg/mL) and number/volume (nM) units. Topical, acetone-deposited
exposures (3D Topical) are presented in total mass (μg) and mass/surface area (μg/cm2) units
This study’s 2D/3D equivalent* exposures: Alternative dose metrics for each exposure route: (as applicable)
2D In-Medium
(μg/mL)
3D In-Medium
(μg)
3D Topical
(μg)
2D In-Medium
(μg)
3D In-Medium
(μg/mL)
3D Topical
(μg/cm2)
3D In-Medium
(nM)
2D In-Medium
(nM)
16 nm-SiO2 85 nm-SiO2 16 nm-SiO2 85 nm-SiO2
0 0 0 0.0 0.0 0.0 0.0 0.00 0.0 0.00
100 150 150 1000.0 167.8 235.9 49.0 0.33 29.2 0.19
200 300 300 2000.0 336.7 473.4 98.4 0.66 58.4 0.39
300 450 450 3000.0 505.6 710.9 147.7 0.99 87.7 0.58
− 1000 1000 − 1111.1 1562.5 324.6 2.17 − −
*Total nanoparticle mass normalised to number of cells per 2D/3D in vitro system (see methods)
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of the test articles examined using the 2D/3D assays
with the in-medium exposures, DLS was carried out for
the 2D (300 μg/mL) and equivalent 3D (450 μg) doses
(Fig. 5). Often nanoparticle agglomerates form in cell
culture growth media, complicating DLS interpretation
as large particulates bias size distributions even when
lowly abundant, since light scatter is proportional to the
sixth-power of particle diameter [44–47]. An approach
using the peak maxima (i.e., size mode) and size range
spanned by 99 % of the frequency distribution by
Fig. 4 Characterising 3D topical nanosilica exposures after deposition in acetone using cryogenic vitrification and scanning electron microscopy:
Representative images 16 nm-SiO2 (a – d), 85 nm-SiO2 (f – i). Particle deposition (false coloured red) varied and was heterogeneous across the
tissue surface. Surface coverage (median = bars, error = range) is summarised in e/j (n = 5). Increasing dose (rows) typically resulted in greater /
deeper surface coverage, with only the far peripheries of the tissue remaining unexposed to nanoparticles at 1000 μg (d, i). Alternative dose
metrics including the 3D equivalent total mass doses with area unit components are provided in Table 2
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particle number was therefore used to compare agglom-
erate size distributions, and permit better correction for
these factors [46].
Relative to water (manufacturer dispersant), in which
agglomerates ranged in size from 9 – 32 nm (Table 1),
the 16 nm-SiO2 showed evidence of increased agglom-
eration in both the 2D and 3D growth medium (M)
types. Size ranges increased, spanning 18–110 nm in
the 2DM and 12–85 nm in 3DM. The 85 nm-SiO2-
behaved similarly, with size ranges increasing in the
2DM to 40–225 nm and to 30–180 nm in the 3DM,
when compared to dispersion in water (50–164 nm).
Although the size ranges established were therefore con-
sistently smaller in the 3DM compared to in the 2DM,
this size difference was equivalent to the addition of
approximately one primary particle to the measured
agglomerate diameter. In all instances, particle incubation
in either 2DM or 3DM resulted in the establishment of
highly similar zeta potentials (around −10 mV).
Comparing 2D and 3D assay dose-responses to the silica
nanoparticles
2D and 3D responses to the 16 nm-SiO2 and 85 nm-
SiO2 in terms of relative cell viability and binucleated
cell MN frequency are presented in Fig. 6. Significant
decreases in cell viability were found in the 2D assays
at doses ≥200 μg/mL for the 16 nm-SiO2 (p < 0.0016)
and ≥100 μg/mL for the 85 nm-SiO2 (p < 0.015). Fur-
thermore, significant MN induction was found for all
exposures of both particles (p < 0.002). Equivalent 3D
exposures had no significant effect on 3D model via-
bility or MN frequency regardless of exposure route
(up to 450 μg) (p > 0.38). For this reason, a single 3D
replicate dosed at 1000 μg was also examined. At this
extreme, well above the 50 % cytotoxicity threshold for
both particle types at equivalent dose in the 2D assay, no
(geno)toxic response was observed for the 3D topical
16 nm-SiO2 and 3D in-medium 85 nm-SiO2 exposures. At
this dose however, a small decrease in cell viability (88 %
of control) and accompanying rise in MN frequency (2.8
fold) was detected for the 16 nm-SiO2 in-medium, and a
sharp decline in cell viability (44 %) was noted for the
85 nm-SiO2 topical exposure. Due to the single replicate
nature of these results, statistical analysis was not
attempted and they are instead presented as preliminary
findings to promote discussions regarding the importance
of cellular uptake assessment in the avoidance of false
positive results in 3D assays. The dose-response data used
in the creation of Fig. 6 are provided in Additional file 7.
Cell uptake: silica nanoparticle localisation in the intact
2D and 3D test systems
To investigate whether the response differences between
the 2D and 3D assays related to differences in cellular up-
take, nanoparticle localisation was investigated at the
harvest time-point using inverted contrast high angle
annular dark-field scanning transmission electron micros-
copy (HAADF-STEM) and EDX spectrometry (Fig. 7).
Fig. 5 Characterising in-medium nanoparticle exposures using DLS: BARS =modal agglomerate hydrodynamic diameter (±99 % distribution
range); POINTS = zeta potential (± SD). Size/charge was calculated by peak analysis of averaged number distributions (10 scans; n = 2). DLS was
carried out at 37 °C for the 300 μg/mL (2D) and equivalent 3D (450 μg) doses. A growth medium reference without nanoparticles was also
assessed during each replicate to ensure nanoparticles were being reliably detected against the serum particulate background. Alternative dose
metrics including the 3D equivalent total mass doses with volume (in-medium exposures) unit components are provided in Table 2
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This imaging mode was chosen as it is sensitive to atomic
number, thus aiding nanoparticle detection, and because it
provided excellent subcellular contrast without need for a
secondary post-fixative (e.g., uranyl acetate) that, in our
experience, can obscure nanoparticles [48]. Analysis was
carried out for the 2D (300 μg/mL) and equivalent 3D
(450 μg) exposures, the highest equivalent doses tested
across both assays.
Analysis of the 16 nm-SiO2 in-medium exposures
(Fig. 7a to c) showed extensive distribution of nanopar-
ticles throughout the pores of the trans-well insert’s
nylon membrane (schematically explained in Fig. 2b).
However, no evidence of exposure/uptake to the basal
cells immediately above the membrane was found, despite
extensive imaging. For the topical exposure route
(Fig. 7d–f ), the 16 nm-SiO2 appeared largely unchanged
from time of topical deposition (cryo-SEM, Fig. 4) with no
evidence of penetration beyond the outmost layers of the
stratum corneum. In contrast, 16 nm-SiO2 2D exposures
showed large numbers of particles in contact with cell
membranes and internalised within vesicles (Fig. 7g–i).
Similar results were found for the 85 nm-SiO2, except parti-
cles were only located along the bottom of the trans-well
membrane, and not throughout it, after 3D in-medium
Fig. 6 (Geno)toxicity assessment of silica nanoparticles exposed at equivalent doses to the 2D and 3D test systems: (a) 16 nm-SiO2, and (b)
85 nm-SiO2. BARS =micronucleus frequency; LINES/POINTS = cell viability. 2D cell cultures (2D) (n = 6, error bars = SD)/3D tissues (n = 2, error bars
= range; except 1000 μg where n = 1) were exposed for 24 h in absence of cyt B via the 3D topical / in-medium or 2D exposure routes.
Genotoxicity was assessed until cell viability decreased below 50 %. Equivalent 2D/3D doses were established by total mass dose normalisation
according to the total number of cells in each culture model at time of inoculation (see Methods). (*) (**) (***) indicate statistical significance relative
to control at p < 0.05, p < 0.01 and p < 0.001 respectively. Alternative dose metrics including the 3D equivalent total mass doses with area (topical
exposures) and volume (in-medium exposures) unit components are provided in Table 2
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Fig. 7 (See legend on next page.)
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exposure (Fig. 7j–l). Again, no evidence of subcutaneous
particle penetration was found via the 3D topical route
(Fig. 7m–o). Fewer cell-membrane bound particles were
found in the 2D exposures (Fig. 7p–r); however, uptake still
occurred with the 85 nm-SiO2 located in vesicles in the ma-
jority of cell sections imaged.
In overview, the particle uptake study showed no expos-
ure to the dividing cells of the 3D models (i.e., for particle
mass doses of ≤ 450 μg), whilst 2D exposures at equivalent
mass per cell doses resulted in direct nanoparticle-cell con-
tact and uptake. Close scrutiny of the 3D in-medium expo-
sures suggests that the cell attachment layer (Fig. 7a, c)
immediately between the insert membrane and basal cells
(schematically explained in Fig. 2b) may have acted as a
physical barrier preventing basal cell exposures.
HAADF-STEM shows this layer is dense and lacks the
pored structure of the trans-well membrane (Fig. 7a
and c). No 2D-cell micrographs supported the possibil-
ity that nanoparticles were free in the cytoplasm or that
direct nanoparticle-nucleus colocalisations occurred.
Further images and EDX spectra for both assays are
presented in Additional files 8, 9, 10, 11 and 12.
Discussion
Commercially available 3D models offer the opportunity
to assess the pathophysiologic activity of test articles in
readily available, standardised systems that are more
reflective of in vivo conditions. The EpiDerm™ model is
available by overnight refrigerated shipment across
North America and Europe, providing testing laborator-
ies access to the same starting materials with proven in-
ter-laboratory reproducibility [32]. In addition to
genotoxicity assessment, protocols that permit use of Epi-
Derm™ tissues for skin irritation and corrosion assessment,
as well as the study of dermal drug delivery and phototox-
icity, have been developed indicating the broad potential
of these models for the assessment of diverse toxicological
endpoints [49–52].
Our experience has shown that one trained user can
expose and harvest up to 48 tissues within the four-day
nano-RSMN period, thus 3D in vitro assays can offer
significantly higher throughput than equivalent in vivo
tests. Although the manual scoring of resultant slides
remains a laborious process, we have previously reported
our successful use of the MetaSystems automated slide
scanning platform to increase RSMN scoring throughput
via semi-automation [36], and efforts to permit fully
automated scoring by flow cytometry are underway [53].
Although there have been recent efforts to validate the
3D RSMN assay for chemicals, as with many test systems,
simply applying these chemical-specific methods to nano-
materials was not possible [11, 28, 29, 31, 32]. Thus, this
work evaluated the utility of MatTek Corporation’s
EpiDerm™ 3D human epidermis model for genetic toxicity
assessment of engineered nanomaterials. Alongside the
general requirement of appropriate dosimetry to permit
2D/3D model comparison, key issues identified in apply-
ing the chemical-RSMN method to nanomaterials in-
cluded: (1) requirement of a sequential cyt B regime, (2) a
dosing regime that does not disrupt the ALI, (3) require-
ment for methods to characterise in-medium and ALI ex-
posures, and (4) requirement for methods to understand
penetration and/or uptake throughout the 3D model.
As already noted, TK6 cells were chosen for the 2D
assays conducted in this study on the basis that they
are recommended in the OECD test guideline for the
in vitro micronucleus assay (i.e., Test Guideline 487)
[42]. Their utility for internationally-accepted, regula-
tory evaluations is based upon: their human origin (i.e.,
as opposed to rodent), the availability of sufficient
historical control data to permit results validation (i.e.,
both intra- and inter-laboratory), their proven ability to
sustain log-phase growth throughout the assay period,
their known maintenance of a stable karyotype, and
their well characterised DNA repair capacities and P53
competency [42]. Collectively, these characteristics
have been shown to reduce the incidence of ‘mislead-
ing positives’ relative to what has been observed for
other cell lines [21, 54, 55]. Therefore, though dermal
cells could have been used for the current study, their
use for in vitro micronucleus frequency assessment
would constitute a significant deviation from the afore-
mentioned, internationally-validated testing strategy
that is routinely employed for regulatory evaluations
and subsequent decision-making. As such, use of TK6
cells was considered the best starting point to permit
comparison of a standard, validated in vitro assay ap-
proach with a new version employing 3D in vitro
models and suitably adapted test methods for nanoma-
terial test articles.
(See figure on previous page.)
Fig. 7 Contrast-inverted HAADF-STEM cross-sectional electron micrographs showing nanoparticle uptake in the 2D and 3D assays: Images were
taken at the harvest time-point for the 300 μg/mL (2D) and equivalent 3D (450 μg) exposures. 16 nm-SiO2 (a – i); 85 nm-SiO2 (j – r). The inset
light micrographs (left) show the position of the electron micrographs/particles (indicated, red outlines) in context of the complete tissue
cross-section after dosing cell cultures (2D) or 3D tissue models via the in-medium or topical exposure routes (presented in triplicate by row).
Magnified regions (green / blue outlines) are indicated on the low magnification images (left column, black outlines) where applicable.
Alternative dose metrics including the 3D equivalent total mass doses with area (topical exposures) and volume (in-medium exposures)
unit components are provided in Table 2
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To date, most RSMN studies have reported dose
(i.e., topically-applied) in mass per volume units [22,
32, 33, 56]. In the context of the chemical-RSMN
method [30], this means 10 μL of a chemical test art-
icle at e.g., 50 μg/mL is applied twice, at 24 h intervals.
In total, the tissue therefore receives 1 μg total mass
of the test article, but the exposure metric is reported
as 50 μg/mL. In contrast, a 2D assay using typical
10 mL suspension monocultures dosed at 0.1 μg/mL
would also utilise a total mass dose of 1 μg. Thus, the
current chemical-RSMN approach to reporting dosim-
etry complicates 2D to 3D comparison for three key
reasons: (1) multiple exposures are not represented,
(2) after vehicle evaporation, a topically applied dose
per unit volume is no longer meaningful, and (3)
differences in the quantity and three-dimensional ar-
rangement of the cells receiving the dose dramatically
influences the probability of test article contact. In an
attempt to make the cellular architectures of the
different test systems under comparison the key differ-
entiating factor, and to provide more comparable 2D
and 3D dosimetry, this study normalised the total mass
of nanoparticles administered to the number of cells in
the respective assay format. This approach was previously
applied in our laboratory to examine the relative sensitiv-
ities of 2D monocultures and the RSMN assay to a range
of chemical test articles [36].
In reality of course, any approach to this 2D/3D dose
normalisation will have limitations in one respect or
another as the exposures are fundamentally different
between the two systems: the 3D topical exposures are
entirely deposited onto the in vitro model after vehicle
solvent evaporation, whilst in-medium deliveries require
diffusion/sedimentation processes for cellular contact.
As no perfect, unbiased way to address these differences
in exposure likely exists, the importance of a compre-
hensive set of tools to understand exposure and cellular
uptake, as demonstrated herein, becomes increasingly
apparent. Ultimately, they provide the means to interpret
differences in 2D/3D dose-response results in the context
of the limitations of any employed dose-normalisation
approach.
Cyt B inhibits actin polymerisation, which is required
for endosome formation in the active cellular uptake
pathways known to be important for nanoparticle in-
ternalisation. Sequential cyt B addition (i.e., nanomater-
ial exposure in absence of cyt B prior to sequential
addition) is therefore important for cytokinesis blocked
MN assessments using nano test articles [11, 28, 29].
Importantly, the accommodations made for this herein
(i.e., dosing for 24 h without cyt B prior to its addition
for 42 h) had no effect on tissue viability or binucleate
frequency. This finding is supported by other chemical-
RSMN studies that have made similar adaptations to
increase exposure time to augment metabolism of
chemical test articles [32]. Tissue growth, differenti-
ation, structure and binucleate frequencies determined
here for the nano-RSMN method are also highly simi-
lar to those reported for the original chemical-RSMN
approach [22, 32, 33, 56].
Topical exposure to water is known to negatively im-
pact EpiDerm™ viability with this finding attributed to
ALI disruption [36]. For this reason, 10 μL acetone, a
commonly used dosing vehicle in dermal rodent studies,
is the recommended chemical-RSMN dosing vehicle
[33]. Here it was also possible to administer the silica
nanoparticle test articles in acetone, without attendant
disruption of colloidal stability [57]. An optimal solvent
vehicle for the nano-RSMN assay should therefore: (1)
evaporate to maintain the ALI, (2) promote colloidal
stability and not degrade the test nanomaterial, (3) not
cause decreased viability or induce genotoxicity, and (4)
yield acceptable tissue surface coverage upon deposition.
Although acetone was a suitable vehicle for this study, it
will not be a universal vehicle since colloidal dispersion
stability and the degradation potential of nanomaterials
depends on their specific composition and physico-
chemical properties [58–60]. Investigation of the range
of solvents compatible with the chemical-RSMN assay
has already been suggested in order to broaden its utility
and application domain [33]. To date, multiple vehicles
including diluted ethanol, dimethylsulphoxide, aceto-
ne:olive oil, water, saline and acetone have been tested
for compatibility with some successes [33, 36, 56]. Other
options, which may be suitable for nanomaterials include
aerosol delivery methods, analogous to those employed
for inhalation exposures for (nano)particle toxicity as-
sessment [61–64]. Commercial systems designed for in
vitro ALI exposures are also available, indeed, they have
been already been successfully used for gases and com-
plex, particle-containing aerosols [65, 66].
It is now well appreciated that comprehensive physico-
chemical characterisation is important for the interpret-
ation of any nanosafety study. Developing methods to
assess nanomaterial exposures for both in-medium and
topical ALI dosing regimes was therefore essential for the
development and establishment of nano-RSMN, and facil-
itated comparisons between the 2D and 3D assay results
presented here.
For both 2D and 3D in-medium exposures, DLS analysis
showed nanoparticle zeta potentials universally increased to
similar charges close to isoelectric zero where colloidal dis-
persions are typically most prone to agglomerate [67, 68].
Accordingly, particle size ranges increased, suggesting de-
creased electrostatic repulsion between individual particles
due to negative surface charge shielding by serum protein
interaction elevated agglomeration [15, 69, 70]. Despite this
evidence for the formation of some agglomerates, the
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particle size range present in 3DM showed that the skin
models were still exposed to a size fraction of individual
nanoparticles via the in-medium dosing route. This pro-
vides further evidence that the cell attachment layer consti-
tuted a barrier and thus a confounding error to 3D in-
medium exposures, as even single particles ≤16 nm were
unable to pass through it and access the apical cell layers.
Exposure characterisation after dosing topically was
also critical for three key reasons: (1) it quantified that
the deposition method resulted in acceptable surface
coverage with the test nanomaterial; (2) it has the poten-
tial to indicate unwanted agglomeration or particle deg-
radation due to choice of an unsuitable dosing vehicle;
(3) it indicated the dose above which the ALI became
submerged by the nano test article. With regard to the
final point, as no evidence of 3D topical penetration was
found, ALI disruption is considered the most likely
explanation of the cell viability decreases observed in
response to the 1000 μg exposures; given the near
100 %, layered surface coverage evidenced during expos-
ure characterisation by cryo-SEM.
Scrutiny of nanoparticle penetration and cellular up-
take was found vital to dose-response interpretation,
with the uptake studying showing that: (1) 3D topical
exposures did not penetrate the stratum corneum skin-
barrier, (2) 3D in-medium exposures were likely pre-
vented from reaching the apical cells due to the imper-
meability of the collagen-coated cell attachment layer,
and (3) 2D in-medium exposures contacted cells and
were taken up in vesicles. Dose-dependent (geno)toxicity
was therefore associated with increasing 2D cellular
exposures, and was absent in 3D models (≤455 μg) since
live-cell nanomaterial exposure did not occur in 3D. In
the absence of corresponding uptake results it was also
not possible to explain the 3D responses observed for
1000 μg exposures. It seems unlikely that increasing
dose suddenly facilitated skin-barrier penetration and
living cell exposures; rather, it seems more likely that
ALI suffocation (i.e., inhibition of gas exchange) from
excessive particle coverage, or failure to restart active
tissue proliferation (as previously observed [36]) are
more likely explanations. Though limited information
regarding real-world dermal exposure concentrations to
nanomaterials exists, it seems reasonable to assert that
these 1000 μg exposures were likely extreme. Neverthe-
less, the OECD test guideline for the in vitro micronucleus
assay states that dose should be increased with the aim to
reach 55 ± 5 % cytotoxicity at the highest tested concen-
tration [42]. Care to not mistake ALI suffocation for test
article toxicity when following this guideline recommen-
dation may therefore prove important with nano-RSMN,
and full determination of the causes of toxicological
responses at very high apical exposures seems to be a pro-
ductive area for subsequent investigation.
In light of the uptake study results, and their implica-
tions regarding the utility of the RSMN for nanosafety
assessment, it is essential to discuss the ability of 3D
reconstructed skin models to represent real human skin.
Although current research is limited, a study of quantum
dot nanoparticles (6 nm; ≤ 24 h exposure) showed simi-
lar, limited penetration in both human skin in vivo and
EpiDerm™ when compared side-by-side [40]. However,
other dermal studies in vivo show that nanomaterials
can penetrate the epidermis, enter circulation and in-
duce organ toxicity, but the process typically requires >
30 days continuous exposure [71], or compromised
skin-barrier integrity [72]. Micron-scaled particles are
also reported to penetrate the stratum corneum more
readily at the site of hair follicles [5, 73]. Although Epi-
Derm™ does not contain these follicular structures, and
exposures are limited to the 72 h during which its 3D
morphology can be retained, these limitations are argu-
ably typical caveats associated with any in vitro test sys-
tem. Interestingly, wound healing has been studied
using reconstructed skin models, suggesting that the
impact of compromised barrier integrity on nanoparti-
cle (geno)toxicity could be studied in vitro [74, 75].
Herein, the negative 3D (geno)toxicity results after
topical exposures were found related to the 3D model’s
skin-barrier properties, which restricted interactions
between the dividing cells and the test article. Whereas
further work to establish how well the barrier proper-
ties of EpiDerm™ reflect in vivo skin is required, it
seems reasonable to assert that these results are more
reflective of actual human hazard than traditional
assays using 2D monocultured cells.
Although investigating the (geno)toxic potential of
amorphous silica was a secondary aim to developing
nano-RSMN, a brief commentary on the positive 2D
(geno)toxicity findings is appropriate. Although com-
parisons of nano(geno)toxicology studies is complicated
by the different exposure durations, dose-ranges, cyt B re-
gimes and cytotoxicity methods used, a review of twenty-
one in vitro studies using amorphous silica found nineteen
that reported decreases in cell viability similar to those
found here [41]. Of specific interest, identical Levasil®
particles caused similar ≤ 22 % and ≤ 36 % decreases
(16 nm and 85 nm-SiO2, respectively) in primary human
lymphocytes (24 h exposure, 31.6 – 316 μg/mL) [76].
Therefore, the 2D cell viability decreases found here are
well-aligned with the majority of reported findings.
Fewer silica studies have thus far considered the MN
endpoint in vitro. An earlier study showed that 34 nm
silica nanoparticles caused ≤ 1.7-fold increases in MN
frequency at ≤ 400 μg/mL (mouse fibroblasts; 24 h cyt B
co-exposure), and similarly, 16 nm, 60 nm and 104 nm
silica particles caused fold increases of ≤ 1.8 at ≤ 300 μg/
mL in human lung carcinoma cells (sequential regime,
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4 h +36 h cyt B) [77]. Other in vitro MN studies have
not shown increases in MN frequency however [76, 78];
interestingly, identical Levasil® nanoparticles did not
cause significant MN induction (≤1000 μg/mL) in pri-
mary human lymphocytes (24 h co-exposure and
sequential 4 h +20 h cyt B methodologies utilised ) [76].
This study’s findings of 2D MN induction in the order
of ≤ 3.0-fold are therefore higher than those previously
reported. This likely relates to both the cell line selection
and cyt B regime used. The TK6 cell line used here is
validated for the MN assay, whilst other investigations
used rodent cells or oncogenically transformed cells that
have differing sensitivities and varying abilities to cope
with genotoxic stress [21, 79, 80]. The exposure period
for uninhibited nanoparticle uptake (without cyt B) was
also substantially longer (24 h) in this study in compari-
son with other investigations (≤4 h). Whereas further
research is required to delineate the mechanism(s)
underlying the 2D chromosomal damage observed
herein, previous studies in other mammalian cell types
indicate vesicularly-internalised nanoparticles can gen-
erate reactive oxygen species, initiate oxidative stress
or mechanically hinder mitotic processes [81–85]. It
seems reasonable to assert that similar mechanisms are
operating here.
Although the MN assay is the ‘gold standard’ test for the
detection of most forms of chromosomal damage that will
be transmitted to the next generation of cells (i.e. non re-
pairable damage), it is not sensitive to some forms of ‘low-
level’ DNA damage including single-strand breaks, alkali
labile sites, DNA-DNA and DNA-protein cross-linking
that might be induced by nanoparticle-mediated oxidative
damage mechanisms [86]. In this regard, it is worth noting
validation of the EpiDerm™ 3D model for the single cell
gel/comet assay, which is sensitive to these forms of
damage, is underway for chemical test articles. At this
stage however, considerable intra- and inter-laboratory
variation is currently reported [53], suggesting further
optimisation of the 3D assay method will be required
before similar adaptation for nanomaterials becomes
an avenue for future research.
Conclusions
This study successfully developed and employed a 3D
‘nano-RSMN’ method using nano test articles to which
dermal exposure is a concern. Although complex and
challenging, rigorous exposure characterisation and
uptake assessment are critical for successful interpret-
ation of in vitro (geno)toxicity results. Thus, to comple-
ment genotoxicity assessment, a package of tools (i.e.,
DLS and cryo-SEM, HAADF-STEM and EDX) with
wide-ranging applicability to other 2D/3D model com-
parisons were employed and demonstrated effective for
the examination of nanomaterial behavior in the 3D in
vitro test environment.
These characterisations revealed the specific import-
ance of the 3D model’s skin-barrier layer in modulating
living-cell exposures to dermally applied nanomaterials,
with the 3D RSMN arguably better reflecting real-world
exposures when compared to traditional 2D monocul-
ture approaches. Although it seems reasonable to assert
that this 3D in vitro system might provide more appro-
priate nanomaterial safety assessments, it is not possible
at the present time to discount the involvement of
wound- or follicle-facilitated exposures of dividing der-
mal cells in adverse effects. Further clear and definitive
comparisons of nanomaterial penetrations in vivo and
EpiDermTM will therefore be required to fully evaluate
nano-RSMN performance. It is also apparent that fur-
ther development of exposure methods that are uni-
formly compatible with a wide range of nanomaterials,
yet able to deliver exposures without air-liquid interface
compromise, will be essential to permit full exploration
of the utility of 3D models for nanotoxicology testing.
In future nanosafety testing strategies, it is suggested that
2D and 3D in vitro assays might prove complimentary.
The potential for DNA damage upon exposure to the
parenchymal cell type of interest could be indicated using
2D exposures, then 3D models of exposure route(s) of
interest could be used to ascertain how likely such expo-
sures are to occur. In the short term however, a more real-
istic objective seems to be the development of 3D in vitro
models to the point where they permit better prioritisation
of animal testing according to exposure risk; facilitating
animal reduction through informed study design.
Methods
General preparation of chemicals and nanomaterials
Chemicals were purchased from Sigma-Aldrich (Gillingham,
UK) unless otherwise stated. The amorphous silica nanopar-
ticles Levasil® 50 (85 nm-SiO2) and Levasil® 200 (16 nm-
SiO2) were donated by Dr. R. Landsiedel (BASF, Germany).
Filter-purified water was prepared by the Milli-Q purifica-
tion system (Merck Millipore, Nottingham, UK).
Cell culture
TK6 human B lymphoblastoid cells (Health Protection
Agency, Wiltshire UK) were cultured in RPMI 1640 con-
taining 1 % L-glutamine (GIBCO, Paisley UK) and 10 %
horse serum (2DM) (BioSer, Sussex UK). EpiDerm™ tis-
sues (#EPI-200-MNA, MatTek, Bratislava, Slovakia) were
delivered by overnight refrigerated shipment and main-
tained using New Maintenance Growth Media (3DM)
(#EPI-100-NMM, MatTek). Cell cultures were incubated
at 37 °C in humidified, 5 % CO2.
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Preparation of nanomaterials for biological experiments
Stock nanoparticle solutions were briefly vortexed then
mixed 1:1 with medium (2D assays) or reagent grade
acetone (3D assays). Solutions were then dispersed
(approx. 288 J/mL) using an ultrasonic bath (#FB15048,
Thermo-Fisher, Loughborough, UK). Dosing was carried
out immediately from these solutions which were pre-
pared fresh for each experimental replicate.
Equivalent dosing: 2D to 3D assay extrapolation
The mass/volume 2D dosing approach was not suit-
able for the 3D models as topical exposures required
evaporation deposition to maintain the ALI. 2D/3D
dose was therefore made equivalent in terms of total
nanoparticle mass to total cell number. E.g., for a 2D dose
of 100 μg/mL, each 10 cm3 culture (#690175 T25 flask,
Greiner Bio-One, Monroe USA) had ~2x106 cells at time
of dosing and received a total nanoparticle mass of
1000 μg. By contrast, EpiDermTM tissues (surface area
0.64 cm2) contained just ~3x105 cells (determined at
harvest after trypsinisation into an individual cell suspen-
sion by haemocytometer count; mean = 304,000; SD =
34,000; n = 8). Therefore to obtain an ‘equivalent’ mass
dose per cell in 3D; a total nanoparticle mass dose of
(1000/6.6) = ~150 μg was required (as there were 2x106/
3 × 105 = 6.6 fewer cells). Alternative dose metrics includ-
ing the 3D equivalent total mass doses with area (topical
exposures) and volume (in-medium exposures) unit com-
ponents are provided in Table 2.
Physico-chemical characterisation: DLS and TEM
preparation
Characterisation was carried out at 300 μg/mL (2D) or
equivalent 450 μg (3D) concentrations. TEM samples
were prepared for primary characterisation by drop-
casting aqueous solutions onto glow-discharge treated,
standard holey carbon TEM support grids (Agar Scien-
tific, Stansted, UK). Nanoparticle primary size distribu-
tions were constructed from individual particle diameter
measurements (n >120) made using ImageJ 1.48v [87].
Agglomerate size (hydrodynamic diameter) and surface
charge (zeta potential) were measured by DLS using a
ZetaSizer Nano ZS instrument (Malvern Instruments
Ltd, Worcestershire, UK). 2D and 3D culture medium
dynamic viscosities (at 37 °C) were determined as
0.757 cP and 0.722 cP respectively by U-tube viscometer
method, and both had a measured refractive index of
~1.34. To gain accurate size information, care was taken
to reproduce the process used to expose cells. 500 μL of
each dispersion was then loaded into a capillary cell
(#DTS1061, Malvern). Samples were allowed to equili-
brate to 37 °C for 2 min prior to measurement. Size
measurements were calculated from the average of ten
100 s scans, and charge measurements from the average
of ten 10 s scans, with measurements repeated in dupli-
cate from independently prepared dispersions. Particle
size was represented by the peak (modal size)/size range
spanned by 99 % of the frequency distribution by num-
ber. A blank growth medium reference was included in
all analyses to ensure particles were reliably detected.
The dispersant dielectric constant was assumed to be
74.5, and Henry’s function was set at the Smoluchowski
approximation of F(ka) = 1.5.
Transmission electron microscopy
TEM was conducted at 200 kV using a Tecnai F20 FEG-
TEM fitted with a high angle annular dark field (HAADF)
detector (FEI, Eindhoven, The Netherlands) and an
INCA 350 EDX system with a 80 mm2 silicon drift de-
tector (Oxford Instruments, Abingdon UK). Images
were recorded using an Orius SC600A CCD camera
(Gatan Inc., Abingdon, UK).
2D RPD and MN assays
The effect of silica nanoparticle exposure to the TK6
cells in terms of cell growth / cytotoxicity was assessed
by relative population doubling (RPD) analysis, with gen-
otoxicity assessment conducted alongside in duplicated
satellite flasks by cytokinesis blocked MN assay (n = 6;
separated across days). Each replicate started by thawing
a new vial of passage seven cells which were cultured for
at least 96 h prior to initiation of experiments. On day
one, 10 mL cell cultures were seeded in T25 flasks
(#690175 Greiner Bio-One) at 2x105 cells/mL (count 1)
and returned to the incubator for 4 h prior to dosing.
Cells were then exposed for 24 h before washing twice
with phosphate-buffered saline (PBS) (GIBCO) and left
to recover for one cell cycle (17 h) (count 2) in the pres-
ence of 3 μg/mL cyt B (#C6762, Sigma) (MN assay).
RPD (%) was calculated as (no. population doublings
(PD) in treated cultures / no. PDs in control cultures) x
100; where PD was defined as (log10(count2/count1))/
log(2). Mitomycin C (MMC) (0.01 μg/mL) (#M7949
Sigma) was used as a positive control. Cells were har-
vested for MN analysis by resuspension in 0.56 % potas-
sium chloride hypotonic solution followed immediately
by 10 min incubation in ‘fixative one’ (5:1:6 methanol-
acetic acid-0.9 % sodium chloride) at 4 °C. Cells were
then washed through four 10 min changes of fixative
two (5:1 methanol-acetic acid; 4 °C), with the cells left in
the final wash overnight at 4 °C. 100 μL volumes of the
fix/cell suspension were then pipetted onto polished, hy-
drated slides. Slides were allowed to air dry, then coun-
terstained with 0.15 μg/mL 4’,6-diamido-2-phenylindole
(DAPI) nuclear stain. The presence of micronuclei in
binucleated cells (six replicates, 2000 binucleates each)
was then assessed automatically using a Axioimager Z2
fluorescent microscope, 1MP CCD camera (Carl Zeiss,
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Cambridge, UK) and Metafer 4 software (MetaSystems
Group, Altlussheim, Germany), using image classifiers
previously optimised for TK6 [23]. All micronucleated
cells were manually validated using the 100X objective.
3D RSMN assay
Upon arrival (+0 h), 900 μL 3DM was aliquoted into
each well of four six-well plates. Moisture was removed
from tissue surfaces using sterile gauze before adding
the tissues to the plates and returning to the incubator
for four hours. Levasil® and mitomycin C (MMC) posi-
tive controls (total mass 0.06 μg topical or 0.03 μg in-
medium) were administered in 10 μL acetone (n = 2)
using a positive displacement pipette (Gilson Scientific,
Luton, UK). Plates were immediately tilted to distribute
the dose across the tissue surface (0.64 cm2/9 mm diam-
eter). After 24 h incubation, 3DM was aspirated and re-
fed containing 3 μg/mL cyt B with this step repeated for
a second time 24 h later. Tissues were then returned to
the incubator for 18 h prior to harvest (+66 h) using the
protocol described in Curran et al., [30]. Trypsinised
cells were then fixed using ice cold 3:1 methanol:acetic
acid (Thermo-Fisher Scientific). 10 μL volumes of this
fix/cell suspension were then pipetted onto polished,
hydrated slides. Slides were stained by immersion in
acridine orange (#A8097, Sigma) diluted to 40 μg/ml in
Gurr buffer at pH 6.8 (#10582-013, GIBCO), then MN
frequencies were assessed manually under UV light using
a BX50 fluorescent microscope (Olympus, Southend-On-
Sea, UK). Two replicates of 2000 binucleated cells were
scored for micronuclei with cell viability assessed accord-
ing to binucleated/mononucleated cell frequencies.
Haematoxylin and eosin tissue staining
Tissues were fixed by immersion in 4 % paraformaldehyde
in PBS for 15 min at 37 °C before changing to fresh fixa-
tive at 4 °C for 15 min. Tissues were then excised from
trans-well inserts using a scalpel, sandwiched between
sheets of filter paper and placed in a Shandon Tissue Cas-
sette (#B1003500AQ, Thermo-Fisher Scientific). Cassettes
were stored in PBS before automatic overnight processing
to paraffin wax at the Cellular Pathology Department of
Singleton Hospital (Swansea, UK). Cycles first involved
dehydration by ethanol series before three changes of
100 % xylene (at 30 °C). Tissues then underwent three
changes of paraffin wax (at 62 °C). Processed blocks were
sectioned at 3 μm thickness using a rotary microtome
(#RM2235, Leica Microsystems, Milton Keynes, UK) and
laid onto polished slides. To stain, slides were first
dewaxed and rehydrated by baking at 60 °C for 1 h be-
fore changing twice through xylene, a reverse ethanol
series and 1 min in water. Slides were then placed in
0.01 % haemotoxylin (#LAMB/170-D, Thermo-Fisher
Scientific) for 3 min. A drop of 0.01 % eosin (#LAMB/
100-D, Thermo-Fisher Scientific) was then added for
5 s before immediately washing in water. Slides were
then dehydrated through an ethanol series then oven
dried for 15 min at 60 °C. Finally, slides were immersed
in xylene before a drop of DPX mounting medium
(#44581, Sigma) was added to secure coverslips. Tissues
were imaged using a BX51 light microscope equipped
with a 3.2 MP Colour View 1 CCD camera and Cell-
Sens Entry software (Olympus, UK).
Cryogenic scanning electron microscopy
The preparation chamber and stage of the S-4800 scan-
ning electron microscope (Hitachi GmbH, Maidenhead,
UK) were purged with liquid nitrogen (3 L/min) to facili-
tate cooling to between -150 and -160 °C. Gas control
was managed using a Polaron Range #PP7483 gas
control unit, #PP7482 turbo pump control unit and
#PP7480 Cryo-SEM preparation control unit (Quorum
Technologies, East Sussex, UK). Immediately after dos-
ing, tissues were mounted by their insert membranes
onto SEM stubs (#AGG3026, Agar Scientific) using
colloidal graphite adhesive (#G303, Agar Scientific). The
mounted specimen stub was then plunged into nitrogen
slush to facilitate vitrification before transfer via a vac-
uum capsule into the pre-cooled preparation chamber of
the microscope. To enhance the contrast of the second-
ary electron images obtained at low accelerating volt-
ages, the electron conductivity of the tissue surface was
modulated by sputter coating with platinum. The prep-
aration chamber was purged with argon at a pressure of
5x10-2 mbar such that a plasma discharge was observed,
before coating with a sputter current of 5-10 mA for
30 s. To avoid damage and movement of the specimen
under cryogenic conditions, imaging was subsequently
conducted under a low 1.0 kV accelerating voltage in
scanning mode. Surface coverage (after normalisation
according to image area) was assessed by masking and
image analysis using ImageJ 1.48v [87]. In the presented
micrographs, Levasil® particles were false-coloured red
to facilitate visualisation.
Cell/tissue preparation for TEM
In the following steps, all buffers were 200 mM and main-
tained pH 7.3. TK6 cells were fixed in 2.5 % Millonig’s
buffered glutaraldehyde (#R1314, Agar Scientific) for
15 min whilst EpiDerm™ tissues were fixed in Millonig’s
buffered 2.5 % glutaraldehyde, 2 % paraformaldehyde for
30 min (37 °C). The respective fixatives were then re-
placed and cells/tissues incubated for a further 4 h at 4 °C.
Excised tissues/pelleted cells (max RPM) were post-fixed
in 1 % phosphate buffered osmium tetroxide (#R1016,
Agar Scientific) for 2 h in the dark at 4 °C. Samples were
dehydrated through an ethanol series before undergoing
two changes of 100 % propylene oxide. Resin infiltration
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involved a 90 min incubation with a 1:1 ratio of medium
resin (#T028, TAAB, Aldermaston, UK) to propylene
oxide, overnight incubation in fresh 100 % resin on a rock-
ing platform at 4 °C, and then baking for 16-24 h in fresh
resin. Resin blocks were trimmed and ultrathin sections
cut at 500 μm2 x 70 nm thickness using an EM-UC7 ultra-
microtome (Leica Microsystems) and an Ultra 45° dia-
mond knife (Diatome, Biel, Switzerland). Sections were
picked up on 150 square mesh copper grids (#G2150C,
Agar Scientific) and sputter coated with ~3.5 nm
carbon (#Q150-TE, Quorum Technologies) prior to
brightfield TEM/EDX spectroscopy and HAADF im-
aging in scanning transmission mode. In the presented
micrographs HAADF images were contrasted inverted for
easy comparison with bright field TEM images and Levasil®
particles were highlighted red to facilitate visualisation.
Statistical analyses
Dose-response significance was assessed using the frame-
work laid out by Johnson et al., [88]. Response data were
assessed for homogeneity of variance and distribution
normality by Bartlett and Shapiro-Wilk tests, respectively,
after log10 transformation. If the transformed data passed
these tests (p > 0.05), comparisons to negative controls
employed one-sided (MN) or two-sided (cell viability) post
hoc Dunnett’s test with alpha set at 0.05. Datasets that
failed either test (p < 0.05) were analysed using the non-
parametric post hoc Dunn’s test. Statistical analyses
were conducted using the online tool DRSMOOTH via
Swansea University’s Mutation Analysis Informatic
Tools website (MutAIT.org) [89].
Additional files
Additional file 1: Brightfield TEM micrographs of the BASF Levasil®
silicon dioxide nanoparticles: 16 nm-SiO2 (a - d), 85 nm-SiO2 (e - h).
(TIF 4314 kb)
Additional file 2: Primary Levasil® size distributions calculated from TEM
micrographs: 16 nm-SiO2 (a), 85 nm-SiO2 (b). (TIF 276 kb)
Additional file 3: Levasil® EDX spectra relative to background:
16 nm-SiO2 (a), 85 nm-SiO2 (b). Regions analysed shown in the inset
image. Copper and carbon signals originate from the TEM grid and its
support film. (TIF 1453 kb)
Additional file 4: Binucleate frequency comparisons between different
3D RSMN methods, cyt B regimes and solvent (acetone) inoculation
routes: The optimised nano RSMN protocol designed to permit topical or
in-medium nanoparticle exposures yielded highly similar frequencies of
binucleated cells to the original protocol designed for chemical test
articles (n = 3, error bars = SD). (TIF 218 kb)
Additional file 5: Characterising 16 nm-SiO2 (false coloured red) topical
3D model deposition in acetone using cryogenic freezing and scanning
electron microscopy: Dose increases down rows; images presented from
separate samples prepared in triplicate. Alternative dose metrics including
the 3D equivalent total mass doses with area (topical exposures) unit
components are provided in Table 2. (TIF 7845 kb)
Additional file 6: Characterising 85 nm-SiO2 (false coloured red) topical
3D model deposition in acetone using cryogenic freezing and scanning
electron microscopy: Dose increases down rows; images presented from
separate samples prepared in triplicate. Alternative dose metrics including
the 3D equivalent total mass doses with area (topical exposures) unit
components are provided in Table 2. (TIF 9112 kb)
Additional file 7: Tabulated dose-response data used in the creation of
Fig. 6: Human B lymphoblastoid cells (TK6) were exposed to the 16 nm-
SiO2 or 85 nm-SiO2 for 24 h in absence of cyt B via the 3D topical (3D-T),
3D in-medium (3D-M) or 2D in-medium (2D) exposure routes. Genotoxi-
city (micronucleus frequency) was assessed until cell viability decreased
below 50 %. Equivalent 2D / 3D doses were established by total mass
dose normalisation according to the total number of cells in each system
at time of inoculation (see Methods). Alternative dose metrics including
the 3D equivalent total mass doses with area (topical exposures) unit
components are provided in Table 2. (CSV 4 kb)
Additional file 8: Contrast inverted HAADF-STEM cross-sectional
micrographs showing 16 nm-SiO2 nanoparticle localisation (indicated, red
outline) in the 3D skin model: Images for each exposure route (450 μg
exposures) are presented alongside undosed negative controls at the
harvest time-point (+66 h) (images presented in triplicate by row). The
inset light micrographs (left) show the position of the electron micrographs/
particles in context of the complete tissue cross-section. Magnified regions
(green/blue outlines) are indicated on the low magnification images (left
column, black outlines) where applicable. Alternative dose metrics including
the 3D equivalent total mass doses with area (topical exposures) and
volume (in-medium exposures) unit components are provided in Table 2.
(TIF 5694 kb)
Additional file 9: Contrast inverted HAADF-STEM cross-sectional
micrographs showing 85 nm-SiO2 nanoparticle localisation (indicated, red
outline) in the 3D skin model: Images for each exposure route (450 μg
exposures) are presented alongside undosed negative controls at the
harvest time-point (+66 h) (images presented in triplicate by row). The
inset light micrographs (left) show the position of the electron micrographs/
particles in context of the complete tissue cross-section. Magnified regions
(green/blue outlines) are indicated on the low magnification images (left
column, black outlines) where applicable. Alternative dose metrics including
the 3D equivalent total mass doses with area (topical exposures) and
volume (in-medium exposures) unit components are provided in Table 2.
(TIF 5412 kb)
Additional file 10: Contrast inverted HAADF-STEM cross-sectional
micrographs showing 16 nm-SiO2 nanoparticle uptake (indicated, red
outline) in 2D TK6 lymphoblastoid cells: Images were taken at the harvest
time-point (+42 h) (300 μg/mL dose). Efforts were made to image >50 cell
sections. Particles could be seen surrounding / bound to cell membranes (a
– c, black) and where readily internalised (red outlines) within vesicles (d – l)
suggesting active uptake. Particle composition/uptake was confirmed by
EDX spectroscopy. (TIF 7535 kb)
Additional file 11: Bright field TEM cross-sectional micrographs showing
85 nm-SiO2 nanoparticle uptake (indicated, red outline) in 2D TK6
lymphoblastoid cells: Images were taken at the harvest time-point
(+42 h) (300 μg/mL dose). Efforts were made to image >50 cell sections.
Particles could be seen surrounding / bound to cell membranes (a – f,
black) and where readily internalised (red outlines) within vesicles (g – l)
suggesting active uptake. Particle composition/uptake was confirmed by
EDX spectroscopy. (TIF 8426 kb)
Additional file 12: Confirming 2D Levasil® uptake using EDX
spectroscopy: (a) 16 nm-SiO2, and (b) 85 nm-SiO2. Areas analysed are shown
in the inset images, with resulting spectra overlaid to compare background
regions (black) to those containing nanoparticles (red). The copper signal
originates from the TEM grid, and the carbon and osmium signals from the
sample preparation method (e.g., the osmium tetroxide fixative used to
enhance contrast and the resin used for embedding). (TIF 1653 kb)
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